Summary

Overview
Global Intraocular lymphoma treatment Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
Intraocular lymphoma is a rare type of B-cell lymphoma. It is formed in white blood cells known as lymphocytes. It is especially common in those over the age of 50 or those with compromised immune systems. Many persons who have this type of eye cancer also have primary central nervous system lymphoma (PCNSL).
The global intraocular lymphoma treatment market encompasses of various drugs such as methotrexate, rituximab, and cisplatin. The market is driven by the factors such as increasing number of people with compromised immune system, growing geriatric population, advancements in research.
Market Dynamics: Drivers and Restraints
The individual with weaker immune system are more susceptible to this disorder
Individuals with weaker immune systems, such as those with HIV/AIDS, organ transplant recipients on immunosuppressive therapy, and those with autoimmune illnesses receiving immunosuppressive pharmaceuticals, are significantly more susceptible to intraocular lymphoma.
For instance, according to the American Academy of Ophthalmology 2022 article, people whose immune systems do not work properly are at risk for getting primary intraocular lymphoma (PIOL). This type of lymphoma is almost always a type of lymphoma called non-Hodgkin’s B cell lymphoma, and it can develop in the retina and in the vitreous inside the eye.
Furthermore, according to the American Cancer Society 2022 article, also notes that people with weakened immune systems have an increased risk for non-Hodgkin lymphoma (NHL). Some long-term infections may increase a person’s risk of lymphoma by forcing their immune system to work harder than usual.
Thus, this increased susceptibility results in a larger patient pool, which drives the demand for intraocular lymphoma drugs. Pharmaceutical companies are increasingly focusing on creating specialized medicines for immunocompromised patients, while clinical trials and research activities are being encouraged to address the specific needs of this vulnerable population.
Market Dynamics: Restraint
The high cost of cancer treatments is a serious global burden, particularly in emerging and underdeveloped nations where government support for healthcare is restricted. This issue derives from the high costs of research and development, severe regulatory requirements, patent protection, and limited access to healthcare. Strategies such as promoting generic pharmaceuticals, negotiating drug pricing, expanding health insurance coverage, investing in research, creating international cooperation, and stressing cancer prevention and early diagnosis can be pursued to help ease this burden.
Segment Analysis
The global intraocular lymphoma treatment market is segmented based on type, drug class, route of administration, distribution channel and region.
The methotrexate segment accounted for approximately 41.2% of the intraocular lymphoma treatment market share
The methotrexate segment is expected to dominate the market with market share of 41.2%. Methotrexate, a chemotherapeutic medication, is commonly used to treat intraocular lymphoma because of its effectiveness in reducing cancer proliferation within the eyes. Methotrexate is a market leader due to its proven track record, relative price compared to newer medicines, and recognized therapeutic utility.
Furthermore, the increasing drug approval is expected drive the segment growth, for instance, in July 2021, Aldeyra Therapeutics has been granted FDA orphan drug designation to ADX-2191 (methotrexate for intravitreal injection) for treatment of primary vitreoretinal lymphoma. It is the first methotrexate preparation specifically formulated for intraocular injection. Thus, owing to the above factors the segment is expected to dominate over the forecast period.
Geographical Penetration
North America accounted for approximately 37.4% of the market share in 2022
The North America region particulary the U.S. is expected to dominate the market owing to the factors such as rising incidence of eye cancer cases with lymphoma, rise in product approvals, increasing number of clinical trial, and presence of key market players in this region
For instance, in April 2023, Polivy (polatuzumab vedotin-piiq) has been approved by the FDA for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Furthermore, the rising prevalence of eye cancer is likely to drive the market in this region. For instance, according to the American Cancer Society's report for 2023, there will be around 3,490 new instances of eye and orbit malignancies in the U.S., the majority of which will be melanomas. This increased prevalence of eye cancer highlights the critical need for improved treatments, including those for intraocular lymphoma. Furthermore, the estimated 430 deaths from eye and orbit tumors demonstrate the significance of developing medicines in the region. As the prevalence of eye cancer, especially intraocular lymphoma, rises in North America, demand for intraocular lymphoma medications is expected to rise and drive market growth in the future years. Thus, owing to the above factors the region is expected to dominate over the forecast period.
COVID-19 Impact Analysis
COVID-19's impact on the intraocular lymphoma market is currently being studied, with little information known especially on this rare kind of disease. However, results from other studies indicate that COVID-19 does not usually directly damage ophthalmic tissues.
Moreover, one notable case report described a patient with intraocular malignant lymphoma who contracted COVID-19 while receiving tirabrutinib treatment, demonstrating the significant issues experienced by people coping with both illnesses at the same time. Furthermore, patient demographics are critical to examine because most people diagnosed with lymphoma of the eye, particularly intraocular lymphoma, are old or have underlying health issues that weaken their immune systems.
Market Segmentation
By Type
• Vitreoretinal
• Uveal
By Drug Class
• Methotrexate
• Cisplatin
• Rituximab
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the intraocular lymphoma treatment market include Pfizer Inc., Fresenius Kabi, Teva Pharmaceuticals Inc., Genentech, Inc., Celltrion Healthcare Co.,Ltd., Viatris Inc., Sandoz International GmbH, F. Hoffmann-La Roche Ltd, AryoGen Pharmed, Hikma Pharmaceuticals PLC among others.
Key Developments
• On July 20, 2021, Aldeyra Therapeutics has been granted FDA orphan drug designation to ADX-2191 (methotrexate for intravitreal injection) for treatment of primary vitreoretinal lymphoma. It is the first methotrexate preparation specifically formulated for intraocular injection.
Why Purchase the Report?
• To visualize the global intraocular lymphoma treatment market segmentation based on type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of intraocular lymphoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global intraocular lymphoma treatment market report would provide approximately 61 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The individual with weaker immune system are more susceptible to this disorder
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. The high cost associated with the treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Epidemiology Analysis
5.2. Porter's Five Force Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Pipeline Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Vitreoretinal*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Uveal
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class
8.2. Methotrexate*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Rituximab
8.4. Cisplatin
8.5. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. Australia
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Pfizer Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Fresenius Kabi
12.3. Teva Pharmaceuticals Inc.
12.4. Genentech, Inc.
12.5. Celltrion Healthcare Co.,Ltd.
12.6. Viatris Inc.
12.7. Sandoz International GmbH
12.8. F. Hoffmann-La Roche Ltd
12.9. AryoGen Pharmed
12.10. Hikma Pharmaceuticals PLC
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us